Novo Nordisk’s Obesity Drug Pipeline Stacked Up For Next 15-20 Yrs: John C Dawber, GBS

In India, the Danish drugmaker Novo Nordisk is the market leader and presently meets over 60 per cent of the country’s insulin supply. Speaking to BW Businessworld in an exclusive interaction, John C. Dawber, CVP and MD, Global Business Services talks about the company’s GLP1 growth story, the market of obesity drugs and their safety profile, building capacities and the company's future ambitions in India